Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers E > Headlines for Endo Pharmaceuticals Holdings Inc. > News item |
Jefferies maintains Endo at buy
Jefferies & Co., Inc. analyst David Windley kept Endo Pharmaceuticals Holdings Inc. at a buy and a $36 price target. The company could trade in the low-30s awaiting new catalysts, such as Opana progress and Rapinyl data. The analyst remains bullish on the stock based on accelerating branded revenue growth and Endo's well-staged pipeline. Shares of the Chadds Ford, Pa.-based pharmaceutical company were down 27 cents, or 0.89%, at $29.91 on volume of 942,654 shares versus the three-month running average of 1,249,190 shares. (Nasdaq: ENDO)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.